Clinical Trials

COVID-19: Fighting a global pandemic with innovation

In this episode of Ideas to Innovation, Clarivate life sciences and healthcare experts reflect on partnering with pharma to combat the pandemic. Listen now.   COVID-19 has presented an enormous global challenge, requiring an unprecedented level of engagement by stakeholders across pharma, research and policy. While SARS-CoV-2 emerged as a novel virus to which humans […]

Top oncology breakthroughs shared at ESMO 2021

Clarivate oncology experts share major takeaways from ESMO and their expected impact on the treatment landscape and patients. As part of our Drugs to Watch™ series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate oncology experts sifted through the more than 2,800 abstracts that were accepted for presentation at the ESMO […]

Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo

Bristol’s Relatlimab/Opdivo (anti-LAG-3/PD-1) therapy is poised to make inroads into its own Opdivo/Yervoy (PD-1/CTLA-4) inhibitor combination share for malignant melanoma. As part of our Drugs to Watch™ series, Clarivate oncology experts Liseth Parra and Rachel Webster review new data shared at ASCO 2021, and implications for patients and life sciences companies.   Compelling Phase III […]

KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma

Merck &Co.’s Keytruda has practice-changing potential as adjuvant therapy for renal cell carcinoma. As part of our Drugs to Watch™ series, Clarivate oncology experts Priyanka Mehra and Sorcha Cassidy review new data shared at the 2021 ASCO Annual Meeting, and implications for patients and life sciences companies.   The renal cell carcinoma treatment landscape continues […]

Roche’s Tecentriq shows promise in resectable NSCLC: key takeaways for the market

Tecentriq, Roche’s flagship anti-PD-L1 therapy, gets one step closer to becoming the first immunotherapy to gain approval as adjuvant therapy in resectable non-small cell lung cancer (NSCLC). As part of our Drugs to Watch™ series, Clarivate oncology experts Arman Esfandiari, Amardeep Singh and Khurram Nawaz review new data shared at ASCO 2021, and implications for […]

Six oncology breakthroughs from Mainland China: Takeaways from ASCO 2021

Clarivate oncology experts analyzed ASCO 2021 abstracts from Mainland China to highlight key trends and breakthrough treatments that are expected to impact the oncology landscape. Mainland Chinese companies were strongly represented at the 2021 ASCO Annual Meeting. As part of our Drugs to Watch™ series spotlighting therapies expected to have significant impact on drug landscapes, […]

Top 10 oncology breakthroughs shared at ASCO 2021

Clarivate oncology experts analyzed more than 2,400 ASCO abstracts and selected the top 10 based on their expected impact on the drug treatment landscape. In the following article, we share our analysis of these exciting breakthroughs, data and takeaways for life sciences executives.   “Equity: Every Patient. Everyday. Everywhere” The ASCO Annual Meeting is the […]

The unmet need for precision medicine in Lyme disease

Lyme disease cases and complications are rising, yet current treatment regimens are proving to be insufficient. Clarivate Senior Science Editor Shyama Ghosh and Managing Editor Stephen DuPraw collaborated with Principal Epidemiologist Swarali Tadwalkar to review the current and emerging treatment landscape and what’s needed to better serve patients.   In the U.S., about 30 million […]

Regulatory response to the COVID-19 pandemic: Careful planning to minimize disruptions

Beyond the need to address the ongoing pandemic itself, regulators also must address the impacts to clinical trials as well as essential supplies of treatments and medicines for other diseases and conditions. In this final blog post of our series, we describe strategies to minimize disruption to ongoing clinical trials, drug manufacturing and essential supplies […]